AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.